Theravac (Cliniques universitaires Saint-Luc)

Theravac is an investigational **therapeutic melanoma vaccine** developed by Cliniques universitaires Saint-Luc and Université Catholique de Louvain. It comprises a genetically detoxified recombinant *Bordetella pertussis* adenylate cyclase toxin protein vector coupled through its catalytic site to the HLA-A2-restricted tyrosinase epitope YMDGTMSQV. The vector targets CD11b-positive antigen-presenting cells through integrin alpha-M beta-2, enabling processing and MHC class I presentation of the tyrosinase epitope and induction of tyrosinase-specific cytotoxic T-cell responses against melanoma cells. Theravac was evaluated in a Phase I/II dose-escalation study in patients with advanced metastatic melanoma expressing tyrosinase. ([clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01331915))

Brand names

Theravac

Other names

recombinant Bordetella pertussis adenylate cyclase toxin-tyrosinase.A2 epitope YMDGTMSQV vaccinerecombinant B. pertussis adenylate cyclase toxin-tyrosinase A2 epitope vaccine